Ropes & Gray represented Sanofi and EQT Life Sciences in their investment in SpliceBio’s $135 million Series B financing. SpliceBio is a Barcelona-based clinical-stage genetic medicines company with a proprietary protein splicing platform. The funding will be used to advance the clinical development of SpliceBio’s lead gene therapy candidate, SB-007 for Stargardt disease.
The Ropes & Gray team included venture capital and emerging companies counsel David Dowling, IP transactions partner Melissa Rones, IP transactions counsel Ryan Murphey and venture capital and emerging companies partner Rajarshi Banerjee.
Stay Up To Date with Ropes & Gray
Ropes & Gray attorneys provide timely analysis on legal developments, court decisions and changes in legislation and regulations.
Stay in the loop with all things Ropes & Gray, and find out more about our people, culture, initiatives and everything that’s happening.
We regularly notify our clients and contacts of significant legal developments, news, webinars and teleconferences that affect their industries.